Noticias Grupo Grünenthal

Bienvenido a la sección de Prensa del Grupo Grünenthal

01 sep 2017

Mark Fladrich takes office as the new CCO of the Grünenthal Group

Aachen, Germany, September 1, 2017. The Grünenthal Group today announces that Mark Fladrich has taken office as new Chief Commercial Officer (CCO). Grünenthal is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation headquartered in Aachen, Germany. In his last appointment Mark Fladrich served as Area Vice President, Southern and Western Europe for AstraZeneca.

Ampliar información ...

04 oct 2016

Gabriel Baertschi takes office as new CEO of Grünenthal Group
as of October 1, 2016

The Grünenthal Group today announces that Gabriel Baertschi has taken office as new CEO of the Grünenthal Group, an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany. The company’s Supervisory Board had named Gabriel Baertschi to become Grünenthal’s new CEO in June 2016. Gabriel Baertschi is joining Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where in his last appointment he served as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques who retires at the end of 2016 after 23 years at Grünenthal.

Ampliar información ...

07 jun 2016

Grünenthal appoints Gabriel Baertschi as Chairman of the Corporate Executive Board and Chief Executive Officer effective October 1, 2016

Swiss native Gabriel Baertschi follows Prof. Dr. Eric-Paul Pâques who retires after 23 years with the company

Grünenthal Group today announced that its Supervisory Board has named Gabriel Baertschi to become Grünenthal’s new CEO as of October 1, 2016. Gabriel Baertschi will join Grünenthal from AstraZeneca, a global, science-led biopharmaceutical business where he currently serves as country president for Japan. He succeeds Prof. Dr. Eric-Paul Pâques, who has been the CEO of the Grünenthal Group. Grünenthal is an independent, family-owned, international research-based pharmaceutical company headquartered in Aachen, Germany with affiliates in Europe, Latin America and the U.S. In 2015, Grünenthal achieved revenues of € 1.2 bn.

Ampliar información ...

12 jun 2015

Grünenthal, Boston Children’s Hospital and Proteus S.A. announce a partnership and development program for neosaxitoxin

  • Partnership program with Proteus S.A. (Chile) and Boston Children’s Hospital (USA)
  • Grünenthal’s Innovative Medicines Unit driving the program in a new approach to research & development

Ampliar información ...

27 dic 2013

Grünenthal completes acquisition of Empresas Andrómaco

Aachen / Santiago de Chile, December 27, 2013. The Grünenthal Group today announced the acceptance of the public tender offer with respect to the acquisition of all issued and outstanding shares of Laboratorios Andrómaco S.A. Inversiones Gruchi Limitada, a subsidiary of Grünenthal GmbH, Germany, has acquired 81.59% of all issued and outstanding shares of Laboratorios Andrómaco S.A. through a public tender offer.

Ampliar información ...

25 nov 2013

Grünenthal launches public tender offer to the shareholders of Empresas Andrómaco

  • Offer period from November 25 to December 24, 2013
  • Offer price of CLP 332.48 per share
  • Offer price represents a premium of 66.99% on the closing price of Sept 6
  • Objective is to acquire all outstanding shares via tender offer

Ampliar información ...

09 sep 2013

Grünenthal signs agreements to acquire Empresas Andrómaco, Chile

  • Grünenthal signed certain agreements with two major shareholders of Empresas Andrómaco, Chile, preparing a potential takeover of the company later in 2013
  • Grünenthal will now conduct a due diligence of Empresas Andrómaco, followed by a potential launch of a public tender offer for all outstanding shares of Laboratorios Andrómaco S.A.
  • Laboratorios Andrómaco S.A. is the Santiago stock exchange listed entity of the Empresas Andrómaco Group

Ampliar información ...

09 sep 2013

Video Statement LATAM Expansion

A Message from Oscar Ferenczi, Executive Vice President Grünenthal Latin America, about the agreements to acquire Empresas Andrómaco, Chile.

Ampliar información ...

04 jul 2013

Grünenthal Group awarded as one of the best employers in Europe and Latin America

Pain specialist participates for the third time in the employee survey and cultural audit of the Great Place to Work® Institute, to reach its self-defined objective of becoming “best employer”.

Ampliar información ...

06 jun 2013

Supporting young scientists on the subject of pain research

EFIC-Grünenthal-Grant awards seven innovative research projects

Brussels/Aachen, 6 June, 2013. For the 8th time the European Federation of IASP® Chapters (EFIC®) in cooperation with the pharmaceutical company Grünenthal Group announced the EFIC-Grünenthal-Grant (E-G-G) – a grant aimed to support young scientists at an early stage of their experimental projects on clinical and human volunteer-based pain research.

Ampliar información ...

Siguientes [1]